



**HAL**  
open science

## How to optimize cancer treatment in older patients: an overview of available geriatric tools

Frédéric Pamoukdjian, Evelyne Liuu, Philippe Caillet, Stéphane Herbaud, Mathilde Gisselbrecht, Johanne Poisson, Pascaline Boudou-Rouquette, Laurent Zelek, Elena Paillaud

### ► To cite this version:

Frédéric Pamoukdjian, Evelyne Liuu, Philippe Caillet, Stéphane Herbaud, Mathilde Gisselbrecht, et al.. How to optimize cancer treatment in older patients: an overview of available geriatric tools. American Journal of Clinical Oncology, 2019, 42 (2), pp.109-116. 10.1097/COC.000000000000488 . hal-04157486

**HAL Id: hal-04157486**

**<https://hal.u-pec.fr/hal-04157486v1>**

Submitted on 10 Jul 2023

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

# How to optimize cancer treatment in older patients: an overview of available geriatric tools

## **Authors:**

F. Pamoukdjian<sup>1, 2</sup>, E. Liuu<sup>3</sup>, P. Caillet<sup>2, 4</sup>, S. Herbaud<sup>5</sup>, M. Gisselbrecht<sup>4</sup>, J. Poisson<sup>4</sup>, P. Boudou-Rouquette<sup>6</sup>, L. Zelek<sup>7</sup>, E. Paillaud<sup>2, 4</sup>.

## **Affiliations:**

<sup>1</sup> APHP, Avicenne Hospital, Department of geriatric medicine, Coordination Unit of Geriatric Oncology, 93000, Bobigny, France.

<sup>2</sup> Université Paris-Est, UPEC, DHU A-TVB, IMRB- EA 7376 CEpiA (Clinical Epidemiology And Ageing Unit), 94000, Creteil, France.

<sup>3</sup> University Hospital of Poitiers, Department of geriatric, Poitiers, France.

<sup>4</sup> APHP, European Georges Pompidou Hospital, Department of geriatric medicine, Geriatric Oncology Unit, 75015, Paris, France.

<sup>5</sup> APHP, Henri Mondor Hospital, Department of geriatric, 94000, Creteil, France

<sup>6</sup> APHP, Cochin Hospital, Department of oncology, 75014, Paris, France.

<sup>7</sup> APHP, Avicenne Hospital, Department of medical oncology, 93000, Bobigny, France.

## **Correspondence:**

Frédéric Pamoukdjian: [frederic.pamoukdjian@aphp.fr](mailto:frederic.pamoukdjian@aphp.fr); APHP, Avicenne Hospital, Department of geriatric medicine, Coordination Unit of Geriatric Oncology, F93000, Bobigny, France.

**Conflicts of interest:** None declared

**Abstract:**

Cancer is a disease of older people, but this age group has often been excluded from clinical trials of cancer, which leads to poor transportability of standardized treatments in older cancer patients. One of the main reasons for the exclusion is the heterogeneity of older people in several domains: social environment, comorbidities, dependency, functional status, nutritional status, cognition status and mood status. Comprehensive geriatric assessment (CGA) aims to assess this heterogeneity and has identified frequent health problems often unknown before therapeutic decisions, which allows for targeted geriatric interventions with or without follow-up and appropriate cancer treatment selection. Several tools and scores have been developed for a complementary approach. These tools screen for vulnerability to select patients who may benefit from a CGA; are predictive tools for survival, post-operative complications, or chemotherapy-related toxicity; are decisional algorithms for cancer treatment; or define a core set of geriatric data to be collected in clinical cancer trials. Here, we present an overview of the geriatric tools that were published in PubMed from 2000 to 2017, that could help in the therapeutic decision-making for older cancer patients.

**Key Words:**

Comprehensive Geriatric Assessment, Clinical Decision-Making, Risk Factors, Clinical Trials, Neoplasms

## **1. INTRODUCTION**

With the ageing of world's population, the incidence of cancer in old people aged 70 years and over has increased markedly [1]. However, older cancer patients have often been excluded from clinical trials of treatment that sets the standards of care in oncology, and the extrapolation of results from younger patients to older cancer patients remains difficult [2]. When considering the heterogeneity of older people, chronological age remains insufficient to assess their health status. Indeed, comorbidities, functional status, nutritional status, mood, cognition and social environment can all interfere with cancer treatment tolerance or compete with cancer as a cause of death.

Ageing is also associated with an increasing risk of frailty. Frailty is defined as an excess vulnerability to stressors, with reduced ability to maintain or regain homeostasis after a destabilizing event. Frailty results from a decrease in physiological functional reserves [3]. It is associated with the risks of disability, institutionalization, unplanned hospitalization, falls, and early death [3]. The support of frailty determinants could reduce or delay the consequences [4].

The assessment of frailty in older cancer patients could help oncologists determine the most appropriate treatment and better assess the benefit/risk balance of performing or omitting specific oncologic interventions. The main goal is to reduce over and under-treatment in older cancer patients. Consequently, scientific societies and health authorities have recommended the implementation of a comprehensive geriatric assessment (CGA) before the cancer treatment decision [5].

Other tools have been recently developed as a complementary approach in order to help with the therapeutic decision. These are screening tools for vulnerability to select older cancer patients who may benefit from a CGA [6] and prognostic scores of survival, post-operative complications, chemotherapy-related toxicity and decisional algorithms for management in older cancer patients. To date, because of the numerous tools and due to the lack of recommendations, the choice of tools and prognostic scores in the geriatric oncology setting depends on the preferences and habits of clinicians, and the local availability of geriatric expertise.

This narrative review focuses on tools and prognostic scores used in current practice (published on PubMed between 2000 and 2017) to help with the therapeutic decision-making in older cancer patients.

## **2. CGA IN OLDER CANCER PATIENTS**

CGA is a multidimensional and multidisciplinary assessment approach that has been progressively used for older cancer patients in the last decade. CGA aims to detect and treat some unknown issues that commonly occur in older patients and interfere with the natural course of cancer and anticancer treatment [7]. CGA identifies frequent health problems often unknown before the therapeutic decision, which allows for targeted geriatric interventions with or without follow-up and appropriate cancer treatment selection [8]. Usually, CGA assesses the following domains: social environment, functional status (mobility and autonomy), nutritional status, cognitive status, mood status, comorbidities and their related polypharmacy [5,9]. For each domain, many reproducible tools are available; there were first validated in a geriatric population, then studied in older cancer patients [10]. A recent systematic review of prospective observational and interventional studies assessing CGA in older cancer patients and published on PubMed between 2000 and 2014, the authors found that CGA revealed the high frequency of impaired geriatric domains: 25% to 75% patients with dependency, 35% to 55% with mobility disorders and/or fall risk, up to 80% with malnutrition, up to 40% with cognitive impairment, up to 65% with mood impairment, up to

80% with more than three comorbidities and up to 40% with inappropriate social environment [11]. Moreover, in a large observational study involving 1967 older cancer patients (median age 76 years) with various sites and stages of cancer, CGA revealed unknown geriatric impairments before the therapeutic decision, that were unknown to the oncologist in 51.2% of patients [12].

Thus, CGA is able to estimate the strengths and weakness of older patients that could interfere with cancer treatment or that could have an independent prognostic value on mortality. CGA may help oncologists select older patients for a standard treatment, those for an adapted treatment, or exclusive supportive cares. Indeed, CGA modifies the therapeutic decision in older cancer patients in 21% to 60% of cases [10–15]. Some studies highlighted domains of CGA that were independently associated with modification of the therapeutic decision in older cancer patients, functional status and nutritional status being the most important [13,14]. In addition, numerous prospective observational and multi-centric studies highlighted the importance of geriatric domains to predict survival in older cancer patients [15]. Indeed, severe comorbidities, malnutrition, dependency in activity of daily living and mobility impairment assessed by the Timed Get Up and Go test (TGUG) were independently associated with the 1-year mortality after a CGA [16]. A slow gait speed, < 0.8 m/s, was also a predictive factor of early death during the 6 months after a CGA, regardless of treatment modalities (i.e., exclusive supportive cares or not) [17].

Furthermore, CGA allows for personalized patient-tailored geriatric interventions in older cancer patients. These geriatric interventions are frequent and various, with mainly nutritional support (70% of cases), social support (46%), psychological support (36%) or cognitive support (21%) [14]. However, few studies have assessed the benefit of geriatric interventions based on CGA results. Nevertheless, it seems that a support and a geriatric monitoring by a nurse may increase the survival in older cancer patients undergoing surgery [18], may result in more appropriate cancer management [19] or may increase the quality of life in older inpatients [20]. Recently, it was highlighted that geriatric interventions based on CGA results were found to increase the completion of chemotherapy and reduce treatment adaptations in older cancer patients [21].

### **3. SCREENING TOOLS FOR FRAILITY IN OLDER CANCER PATIENTS**

Because CGA is time-consuming, and with the limited number of geriatricians trained in oncology, the assessment is not implementable for all older cancer patients and is probably not necessary for the most robust of them. Conversely, the most vulnerable patients remain the target for the implementation of CGA. Thus, the International Society of Geriatric Oncology (SIOG) recommends a two-step approach, starting with screening older cancer patients who need a CGA [6,22]. According to the SIOG guidelines, this screening should be done before a therapeutic decision, should be easy and quick, and should target a high sensitivity and negative predictive value [6]. To date, and because of the lack of consensual definition of vulnerability in geriatric oncology, available screening tools have defined vulnerability by the number of impaired geriatric domains in the CGA. Thus, the definition of vulnerability across studies varies from 1 and 2 impaired geriatric domains [22]. Moreover, the number of geriatric domains used varies widely across studies (3-8), as does the number of tools used in each geriatric domain (4-10). Consequently, the diagnostic performance of screening tools for vulnerability is heterogeneous (Table 1) [22–39][23–40].

A recent update of the SIOG guidelines reported that the most-used screening tools for vulnerability were the Geriatric 8 index (G8 index), the Vulnerable Elders Survey-13 (VES-13) and the Eastern Cooperative Oncology Group Performance Status (ECOG-PS) [6]. The ECOG-PS is the most familiar tool for oncologists to estimate the performance status of their

older patients. However, Repetto L et al [41] showed the lack of accuracy of this tool in 363 older cancer patients (median age 72 years) with solid cancers or hematological malignancies. Indeed, in this study, patients with a good ECOG-PS (i.e., score < 2) had at least two comorbidities, and 9.3% and 37.7% were dependent in activities of daily living (ADL) and in instrumental ADL (IADL), respectively [41]. The G8 index should be preferred according to the SIOG recommendations, the French National Institute of Cancer and the French Society of Geriatric Oncology. Indeed, the G8 index is one of the rare screening tools specifically designed in a population of older patients with cancer [23]. It has been validated in a large independent cohort of 1435 analyzed patients (1674 included) with solid cancer and non-Hodgkin's lymphoma [24]. The G8 index is easy and quick to administer and its diagnostic performance is acceptable, with sensitivity 76.5% (95% confidence interval [CI]: 73.9-78.9) and specificity 64.4% (95% CI: 58.6-70.0) to detect at least one impaired geriatric domain. Nevertheless, the diagnostic performance of the G8 index to screen for vulnerability varies widely across studies (sensitivity: 65-97%, specificity: 3-100%). The main reason for this variation is probably the heterogeneity of gold standards, the number of tools used in CGA and the heterogeneity of studied populations included in clinical studies [22]. Thus, improvements in the G8 index were proposed in 2016. Results of two French cohort studies of patients  $\geq 70$  years old with cancer at various sites and stages were published: the modified G8 index and the G8 IADL-modified index [42,43]. These screening tools derived from the G8 index included other parameters of interest in geriatric oncology such as functional status and some comorbidities. Thus, diagnostic performance (sensitivity and specificity) was increased: for the G8 modified index, sensitivity was 89.2% (95% CI: 86.5-91.5) and specificity 79.0% (95% CI: 69.4-86.6) to detect at least one impaired geriatric domain [42]; for the G8 IADL-modified index, sensitivity was 88% (95% CI: 84-91) and specificity 69% (95% CI: 41-89) to detect at least one impaired geriatric domain [43]. Furthermore, diagnostic performance of the G8 index varied across cancer sites: sensitivity and specificity were 90% (95% CI: 82-95%) and 23% (95% CI: 5-54%) for colorectal cancer and 95% (95% CI: 88-99%) and 50% (95% CI: 7-93%) for urological malignancies [22]. These variations in diagnostic performances of the G8 index suggest the need for vulnerability screening tools adapted to cancer site and cancer treatment modality.

#### **4. PROGNOSTIC SCORES AND MORTALITY IN OLDER CANCER PATIENTS**

In practice, estimating the patient's overall survival at the time of the treatment decision may be useful but challenging. First, we retrieved numerous scores that have been validated in large epidemiologic cohorts: Carey's score [44] and Walter's score [45] for estimating overall inpatient's survival at 1 year, and Gagne's score [46] and Lee's score [47] for estimating overall outpatient survival at 3 and 4 years, respectively. All these scores consider comorbidities with cancer, nutritional status and dependency as covariates, which are variables of interest in older cancer patients. Indeed, these scores could help in estimating the patient's overall survival with and without cancer. Consequently, they could weigh the effects of ageing and comorbidities on survival at the time of the decision-making process. To our knowledge, no studies have validated these scores in the geriatric oncology setting. Of note, these scores were developed in an epidemiological context and unlike the CGA, probably do not reflect the individual variability in current practice. Second, we retrieved a recent composite score specifically developed for older cancer outpatients for predicting 1-year mortality: the Onco-Multidimensional Prognostic Index (onco-MPI) [48]. This score, based on the CGA before a therapeutic decision, was developed in 658 newly diagnosed outpatients (mean age 77.1 years) with cancer at various sites and various stages. Besides age, cancer site and stage, other variables of interest in geriatric oncology were included: body mass index,

dependency (ADL and IADL scores), ECOG-PS, comorbidities (Cumulative Illness Rating Scale-Geriatric [CIRS-G] score), number of drugs, cognition (Mini Mental State Examination [MMSE] score) and social environment. Use of the Onco-MPI classified patients into three groups at risk of death during the 1-year follow-up: low, medium and high risk. To our knowledge, the Onco-MPI was not externally validated. Table 2 summarizes the prognostic performance of these scales based on area under the receiver operating characteristic curve (AUC) or survival c-index. The choice of score depends on preferences and habits of clinicians and the local availability of geriatric expertise.

## **5. TOOLS FOCUSING ON RISK OF POST-OPERATIVE COMPLICATIONS IN OLDER CANCER PATIENTS**

Surgery remains the cornerstone of treatment for localized cancers [49]. Despite the improvements in surgical management of cancers, post-operative complications are highly prevalent in older patients (35–50%), of which half of complications will be major [47–49][48–50][48–50]. In a large survey of 939 150 US patients (two-thirds aged 65 years and over) hospitalized for a major cancer surgery (gastrointestinal tract, genitourinary tract, breast and prostate), 9.2% experienced at least one geriatric event (dehydration, delirium, pressure ulcers, falls and fractures) during the hospitalization. These complications more often concerned the oldest patients (age  $\geq 75$  years) with a Charlson's comorbidity score  $\geq 2$ , and with bladder, ovary, colorectal, pancreas or stomach cancer [51].

Accordingly, pre-surgery assessment of older patients is needed to limit post-operative complications. Thus, the SIOG recommends the implementation of a multidimensional pre-operative assessment in cancer patients aged 70 years and older when surgery is indicated, named Preoperative Assessment in Elderly Cancer Patients (PACE). PACE includes numerous tools that are summarized in Table 3 [51–58][52–59]. In a study conducted by a SIOG surgical task force, involving 460 patients with mean age 76.9 years and various cancer sites (breast, gastrointestinal tract, urinary tract), the PACE was used before surgery [50]. Among tools used, the American Society for Anaesthesiologist scale (ASA)  $\geq 2$  was the only tool predicting post-operative complications, whereas 30-day mortality was associated with post-operative complications, cancer extension, and major surgery. Moreover, in this study, ADL, IADL and ECOG-PS were independently associated with a long hospitalization. To our knowledge, the PACE has not been externally validated, and no score to predict post-operative complications has been specifically developed in older patients undergoing surgery for cancer.

Nevertheless, numerous impaired geriatric domains were found independently associated with post-operative complications in older cancer patients. Indeed, in a recent systematic review, the authors retrieved 17 observational cohort studies conducted between 2004 and 2015 in older patients undergoing surgery for cancer [60]. Functional status including mobility, nutritional status, comorbidities and cognition predicted post-operative complications: overall mortality, disease-specific survival, major Clavien-Dindo score (i.e.,  $\geq 3$  complications during the post-operative 90 days), and discharge to nursing home [60]. More recently, in a study of 263 consecutive older patients (median age 76 years) undergoing elective surgery for solid cancers (breast, thyroid, gastrointestinal, genitourinary), 19.5% of patients experienced a major complication (Clavien-Dindo score  $\geq 3$ ) during the post-operative 30 days [61]. In this study, TGUG score  $> 20$  s and ASA scale score  $\geq 3$  were independently associated with major post-operative complications and a prolonged hospital stay. Impaired geriatric domains were also found specifically associated with post-operative delirium. Indeed, in a recent study of 416 consecutive old patients (median age 80 years) undergoing major carcinologic surgery (gastro-intestinal, hepatobiliary, genitourinary, head and neck), 19% experienced post-

operative delirium according to the confusion assessment method. Charlson's comorbidity score  $\geq 3$ , IADL dependency and history of fall in the last 6 months were independently associated with post-operative delirium (AUC: 0.63) [62]. In another study, for 118 consecutive patients aged 75 years and over and undergoing major abdominal surgery, post-operative delirium occurred in 24%. ASA scale score  $\geq 3$ , TGUG score  $> 20$  s and post-operative tramadol administration were independently associated with post-operative delirium [63].

Furthermore, in one study conducted in Korean people, the authors proposed a 1-year post-operative mortality prognostic index, specifically developed in older patients with and without cancer and undergoing surgery [64]. In this study, a multidimensional frailty score (MFS) based in part on CGA domains was established in 275 consecutive older patients with mean age 75.2 years and before surgery, including 53.8% with malignant disease. The MFS involved nine items: malignant disease, Charlson's comorbidity index; albumin level, Mini Nutritional Assessment score, and mid-arm circumference for nutritional status; ADL and IADL scores for functional status; MMSE score; and nursing delirium screening for cognition [64]. The MFS was independently associated with 1-year post-operative mortality and discharge to a nursing facility but not post-operative complications. In addition, the MFS was a better discriminative score by comparison with the ASA scale regardless of outcome (AUC = 0.82 for 1-year mortality, AUC = 0.72 for post-operative complications and AUC = 0.77 for discharge to a nursing facility). In contrast, the AUC values with the ASA scale were 0.64, 0.57 and 0.59, respectively [64]. Nevertheless, and to our knowledge, this index was not externally validated in older cancer patients and in Western countries.

Post-operative risk depends on the type of surgery, and homogenization of this risk with a single score in older cancer patients remains difficult. Further studies are needed to validate a good prognostic score to predict post-operative complications in older cancer patients.

## **6. TOOLS FOCUSING ON THE RISK OF CHEMOTHERAPY-RELATED TOXICITY IN OLDER CANCER PATIENTS**

Estimating the patient's toxicity risk ( $\geq$  grade 3) related to chemotherapy is one of the main issues in older cancer patients scheduled for chemotherapy. Indeed, patients aged 65 years and older more commonly experience chemotherapy-related toxicity than do younger patients [65]. This fact could be explained by the heterogeneity of older patients [66]. Like post-operative risk, chemotherapy-related toxicity was found associated with numerous CGA components in older cancer patients. The geriatric domains poor functional status, comorbidities, polypharmacy, malnutrition, cognitive impairment, depressive mood, inappropriate social environment, and frailty assessed by Fried's criteria were independently associated with chemotherapy-related toxicity in most observational cohort studies conducted in older cancer patients [66].

*De facto*, CGA remains a cornerstone to assess pre-therapeutic vulnerabilities when chemotherapy is considered. Nevertheless, two prognostic scores were specifically developed to predict chemotherapy-related toxicity in older cancer patients to help oncologists with therapeutic decision-making. The first score, published and validated in 500 older patients (mean age 73 years) with various solid cancers (lung, gastrointestinal, gynecologic, breast and genitourinary) at various stages (I to IV) was the Cancer and Aging Research Group (CARG) toxicity tool (Table 4) [67]. This score was compared with the Karnofsky performance status and showed better discrimination according to the AUC (0.72 vs 0.53, respectively). The second score, the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH), was validated in 518 older patients (mean age 75.5 years) with various solid cancers (lung, breast, colorectal, bladder) at various stages (I to IV), and hematological malignancies (Table



5) [68]. In contrast to the CARG toxicity tool only considering the overall risk of toxicity, the CRASH estimates hematological and non-hematological toxicity risk. In addition, the CRASH takes into account the type of chemotherapy, whereas the CARG toxicity tool considers single versus poly-chemotherapy. To date, no external validation and no comparison of prognostic performance between both scores are available, and the choice of score depends on the preferences and habits of clinicians. Use of the CRASH also depends on the local availability of geriatric expertise since it uses numerous geriatric tools. Whatever the tool used, the adaptation of chemotherapy in older cancer patients is still not consensual and is based on two practical attitudes: secondary adaptation to tolerance of first cycles or immediate dose reduction and then strengthening of chemotherapy dose-adjusted to patient tolerance. Overall, joint monitoring (oncologists and geriatricians) should be implemented for older vulnerable cancer patients scheduled for chemotherapy.

## **7. DECISION TREES FOR MANAGEMENT FOR OLDER CANCER PATIENTS**

Different decision-making trees for management for older cancer patients have been proposed (Table 6). The first algorithm for therapeutic decision-making in geriatric oncology based on the CGA findings was suggested by Balducci L and Belghe C [69]. This algorithm classified older cancer patients as “robust patients” for whom a standard strategy against cancer was proposed, “vulnerable patients” for whom an adapted strategy was proposed, or “frail patients” for whom exclusive supportive care was proposed [69]. Another classification was suggested by Droz et al. and was used in the SIOG guidelines for older men with prostatic cancer (SIOG-1) [70]. This last classification was updated with inclusion of the G8 index (SIOG-2) [71]. These classifications are based on clinical expertise and consensus.

Recently, a new statistical approach based on latent classes analysis (LC) classified patients into homogeneous health groups according to CGA domains [72]. Four phenotypes were identified: relative good health, malnourished, cognitive and/or mood impaired, and globally impaired. More recently, the four classifications (i.e., Balducci, SIOG-1, SIOG-2, and LC) were compared in a study of 763 older patients (mean age  $80 \pm 5.7$  years) with solid cancers and hematological malignancies [73]. All four classifications had good prognostic performance in predicting 1-year mortality and 6-month unplanned hospitalizations. They showed variation in performance across tumor sites, with lower discrimination in colorectal cancer and better discrimination in breast and prostate cancer.

To date, because of lack of sufficient scientific data, consensus is lacking on an algorithm for decision-making about cancer treatments and for stratifying older patients with cancer in clinical trials. One clinical trial compared a standard strategy for chemotherapy allocation based on age and the ECOG-PS to an experimental strategy based on Balducci’s classification in older patients with advanced lung cancer. In this clinical trial, the use of an algorithm based on geriatric domains assessed by a pneumologist without geriatric interventions was amenable to reduce chemotherapy-related toxicity but did not affect overall survival [74].

## **8. GERIATRIC MINI DATASET FOR CLINICAL TRIALS**

The collection of a minimum dataset of geriatric data should be encouraged in clinical trials. It may provide a clearer description of characteristics of older patients enrolled in clinical trials, with a better chance to extrapolate the applicability of results to standard practice. Moreover, it may be essential for comparing and merging data from different studies.

The European Organisation for Research and Treatment of Cancer recommended the use of a standardized minimum dataset for assessing the global health and functional status of older populations [75]. This minimum dataset (minDS) consisted of the G8 index, IADL questionnaire, Charlson's Comorbidity Index, and data on social situation. Hurria et al. [76] developed a tool, the geriatric assessment for the Cancer and Leukemia Group B trial (CALGB) based on 75 items, primarily patient self-administered, and with only a small part requiring the assistance of a healthcare provider. The approach and the scientific method used to define the minDS or CALGB were not clearly explained, and the appropriation of the minDS for target users was not studied. By a Delphi consensus method followed by an international survey, Paillaud et al. developed a user-friendly tool (Geriatric COre Data sEt [G-CODE]) that can be used by any cancer health professional for collecting geriatric data in cancer clinical trials at baseline in the curative or palliative setting regardless of tumor type [77].

### **CONCLUSIONS:**

During the last twenty years, CGA has become a reference to help with the therapeutic-decision making in older cancer patients. Several tools were developed in a complementary approach to select patients who may benefit from a CGA, to predict treatment complications and survival, and to promote clinical cancer trials in older cancer patients.

## REFERENCES:

1. Ferlay Jacques, Soerjomataram Isabelle, Dikshit Rajesh et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer*. 13 sept 2014;136(5):E359- 86.
2. Le Saux O, Falandry C, Gan HK et al. Inclusion of elderly patients in oncology clinical trials. *Ann Oncol*. sept 2016;27(9):1799- 804.
3. Walston J, Hadley EC, Ferrucci L et al. Research Agenda for Frailty in Older Adults: Toward a Better Understanding of Physiology and Etiology: Summary from the American Geriatrics Society/National Institute on Aging Research Conference on Frailty in Older Adults. *J Am Geriatr Soc*. 1 juin 2006;54(6):991- 1001.
4. Gill TM, Gahbauer EA, Allore HG et al. Transitions between frailty states among community-living older persons. *Arch Intern Med*. 27 févr 2006;166(4):418- 23.
5. Wildiers H, Heeren P, Puts M et al. International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. *J Clin Oncol* 2014 Aug 20;32(24):2595-603.
6. Decoster L, Puyvelde KV, Mohile S et al. Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations. *Ann Oncol*. 1 févr 2015;26(2):288- 300.
7. Caillet P, Pamoukdjian F, Obraztsova A et al. Comprehensive geriatric assessment in cancer patients. In Pilotto A, Martin FC, editors. *Comprehensive Geriatric Assessment*. Cham: Springer International Publishing; 2018 [cited 2018 Jun 4]. (Practical Issues in Geriatrics). Available from: <http://link.springer.com/10.1007/978-3-319-62503-4>.
8. Hurria A, Stuart M, Lichtman, Gardes J et al. Identifying vulnerable older adults with cancer: integrating geriatric assessment into oncology practice. *J Am Geriatr Soc*. oct 2007;55(10):1604- 8.

9. Gnjdjic D, Hilmer SN, Blyth FM et al. Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. *J Clin Epidemiol.* sept 2012;65(9):989- 95.
10. Mohile SG, Dale W, Somerfield MR et al. Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology Summary. *J Oncol Pract.* juill 2018;14(7):442- 6.
11. Caillet P, Laurent M, Bastuji-Garin S et al. Optimal management of elderly cancer patients: usefulness of the Comprehensive Geriatric Assessment. *Clin Interv Aging.* 2014;9:1645- 60.
12. Kenis C, Bron D, Libert Y et al. Relevance of a systematic geriatric screening and assessment in older patients with cancer: results of a prospective multicentric study. *Ann Oncol.* mai 2013;24(5):1306- 12.
13. Marengo D, Marinello R, Berruti A et al. Multidimensional geriatric assessment in treatment decision in elderly cancer patients: 6-year experience in an outpatient geriatric oncology service. *Crit Rev Oncol Hematol.* 1 nov 2008;68(2):157- 64.
14. Caillet P, Canoui-Poitrine F, Vouriot J et al. Comprehensive Geriatric Assessment in the Decision-Making Process in Elderly Patients With Cancer: ELCAPA Study. *J Clin Oncol.* 20 sept 2011;29(27):3636- 42.
15. Puts MTE, Santos B, Hardt J et al. An update on a systematic review of the use of geriatric assessment for older adults in oncology. *Ann Oncol.* 1 févr 2014;25(2):307- 15.
16. Ferrat E, Paillaud E, Laurent M et al. Predictors of 1-Year Mortality in a Prospective Cohort of Elderly Patients With Cancer. *J Gerontol A Biol Sci Med Sci.* sept 2015;70(9):1148- 55.
17. Pamoukdjian F, Lévy V, Sebbane G et al. Slow Gait Speed Is an Independent Predictor of Early Death in Older Cancer Outpatients: Results from a Prospective Cohort

Study. *J Nutr Health Aging*. 2017;21(2):202- 6.

18. McCorkle R, Strumpf NE, Nuamah IF et al. A specialized home care intervention improves survival among older post-surgical cancer patients. *J Am Geriatr Soc*. déc 2000;48(12):1707- 13.

19. Goodwin JS, Satish S, Anderson ET et al. Effect of nurse case management on the treatment of older women with breast cancer. *J Am Geriatr Soc*. sept 2003;51(9):1252- 9.

20. Rao AV, Hsieh F, Feussner JR et al. Geriatric evaluation and management units in the care of the frail elderly cancer patient. *J Gerontol A Biol Sci Med Sci*. juin 2005;60(6):798- 803.

21. Kalsi T, Babic-Illman G, Ross PJ et al. The impact of comprehensive geriatric assessment interventions on tolerance to chemotherapy in older people. *Br J Cancer*. 28 avr 2015;112(9):1435- 44.

22. Liuu E, Caillet P, Curé H et al. [Comprehensive geriatric assessment (CGA) in elderly with cancer: For whom?]. *Rev Med Interne*. juill 2016;37(7):480- 8.

23. Bellera CA, Rainfray M, Mathoulin-Pélessier S et al. Screening older cancer patients: first evaluation of the G-8 geriatric screening tool. *Ann Oncol*. 1 août 2012;23(8):2166- 72.

24. Soubeyran P, Bellera C, Goyard J et al. Screening for Vulnerability in Older Cancer Patients: The ONCODAGE Prospective Multicenter Cohort Study. *PLOS ONE*. déc 2014;9(12):e115060.

25. Smets IHGJ, Kempen GIJM, Janssen-Heijnen MLG et al. Four screening instruments for frailty in older patients with and without cancer: a diagnostic study. *BMC Geriatr*. 2014;14:26.

26. Kenig J, Zychiewicz B, Olszewska U et al. Screening for frailty among older patients with cancer that qualify for abdominal surgery. *J Geriatr Oncol*. 1 janv 2015;6(1):52- 9.

27. Baitar A, Fraeyenhove FV, Vandebroek A et al. Evaluation of the Groningen Frailty

Indicator and the G8 questionnaire as screening tools for frailty in older patients with cancer. *J Geriatr Oncol.* 1 janv 2013;4(1):32- 8.

28. Hamaker ME, Mitrovic M, Stauder R. The G8 screening tool detects relevant geriatric impairments and predicts survival in elderly patients with a haematological malignancy. *Ann Hematol.* 2 févr 2014;93(6):1031- 40.

29. Holmes HM, Des Bordes JKA, Kebriaei P et al. Optimal screening for geriatric assessment in older allogeneic hematopoietic cell transplantation candidates. *J Geriatr Oncol.* 1 oct 2014;5(4):422- 30.

30. Kenis C, Decoster L, Van Puyvelde K et al. Performance of two geriatric screening tools in older patients with cancer. *J Clin Oncol.* 1 janv 2014;32(1):19- 26.

31. Liuu E, Canoui-Poitaine F, Tournigand C et al. Accuracy of the G-8 geriatric-oncology screening tool for identifying vulnerable elderly patients with cancer according to tumour site: The ELCAPA-02 study. *J Geriatr Oncol.* 1 janv 2014;5(1):11- 9.

32. Velghe A, Petrovic M, De Buyser S et al. Validation of the G8 screening tool in older patients with aggressive haematological malignancies. *Eur J Oncol Nurs.* déc 2014;18(6):645- 8.

33. Hentschel L, Rentsch A, Lenz F et al. A Questionnaire Study to Assess the Value of the Vulnerable Elders Survey, G8, and Predictors of Toxicity as Screening Tools for Frailty and Toxicity in Geriatric Cancer Patients. *Oncol Res Treat.* 2016;39(4):210- 6.

34. Pamoukdjian F, Canoui-Poitaine F, Longelin-Lombard C et al. Diagnostic performance of gait speed, G8 and G8 modified indices to screen for vulnerability in older cancer patients: the prospective PF-EC cohort study. *Oncotarget.* 1 août 2017;8(31):50393- 402.

35. Kellen E, Bulens P, Deckx L et al. Identifying an accurate pre-screening tool in geriatric oncology. *Crit Rev Oncol Hematol.* sept 2010;75(3):243- 8.

36. Biganzoli L, Boni L, Becheri D et al. Evaluation of the cardiovascular health study (CHS) instrument and the Vulnerable Elders Survey-13 (VES-13) in elderly cancer patients. Are we still missing the right screening tool? *Ann Oncol.* 1 févr 2013;24(2):494- 500.
37. Mohile SG, Bylow K, Dale W et al. A pilot study of the vulnerable elders survey-13 compared with the comprehensive geriatric assessment for identifying disability in older patients with prostate cancer who receive androgen ablation. *Cancer.* 15 févr 2007;109(4):802- 10.
38. Luciani A, Ascione G, Bertuzzi C et al. Detecting disabilities in older patients with cancer: comparison between comprehensive geriatric assessment and vulnerable elders survey-13. *J Clin Oncol.* 20 avr 2010;28(12):2046- 50.
39. Molina-Garrido MJ, Guillen-Ponce C. Comparison of two frailty screening tools in older women with early breast cancer. *Crit Rev Oncol Hematol.* 1 juill 2011;79(1):51- 64.
40. Augschoell J, Kemmler G, Hamaker ME et al. PPT and VES-13 in elderly patients with cancer: evaluation in multidimensional geriatric assessment and prediction of survival. *J Geriatr Oncol.* 1 oct 2014;5(4):415- 21.
41. Repetto L, Fratino L, Audisio RA et al. Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study. *J Clin Oncol.* 15 janv 2002;20(2):494- 502.
42. Martinez-Tapia C, Canoui-Poitaine F, Bastuji-Garin S et al. Optimizing the G8 Screening Tool for Older Patients With Cancer: Diagnostic Performance and Validation of a Six-Item Version. *Oncologist.* févr 2016;21(2):188- 95.
43. Petit-Monéger A, Rainfray M, Soubeyran P et al. Detection of frailty in elderly cancer patients: Improvement of the G8 screening test. *J Geriatr Oncol.* mars 2016;7(2):99- 107.
44. Carey EC, Covinsky KE, Lui L-Y et al. Prediction of Mortality in Community-Living

Frail Elderly People with Long-Term Care Needs. *J Am Geriatr Soc.* 1 janv 2008;56(1):68- 75.

45. Walter LC, Brand RJ, Counsell SR et al. Development and Validation of a Prognostic Index for 1-Year Mortality in Older Adults After Hospitalization. *JAMA.* 20 juin 2001;285(23):2987- 94.

46. Gagne JJ, Glynn RJ, Avorn J et al. A combined comorbidity score predicted mortality in elderly patients better than existing scores. *J Clin Epidemiol.* juill 2011;64(7):749- 59.

47. Lee SJ, Lindquist K, Segal MR et al. Development and Validation of a Prognostic Index for 4-Year Mortality in Older Adults. *JAMA.* 15 févr 2006;295(7):801- 8.

48. Brunello A, Fontana A, Zafferri V et al. Development of an oncological-multidimensional prognostic index (Onco-MPI) for mortality prediction in older cancer patients. *J Cancer Res Clin Oncol.* mai 2016;142(5):1069- 77.

49. Kristjansson SR, Farinella E, Gaskell S et al. Surgical risk and post-operative complications in older unfit cancer patients. *Cancer Treat Rev.* oct 2009;35(6):499- 502.

50. PACE participants, Audisio RA, Pope D et al. Shall we operate? Preoperative assessment in elderly cancer patients (PACE) can help. A SIOG surgical task force prospective study. *Crit Rev Oncol Hematol.* févr 2008;65(2):156- 63.

51. Tan H-J, Saliba D, Kwan L et al. Burden of Geriatric Events Among Older Adults Undergoing Major Cancer Surgery. *J Clin Oncol.* 10 avr 2016;34(11):1231- 8.

52. Katz S, Downs TD, Cash HR et al. Progress in development of the index of ADL. *Gerontologist.* 1970;10(1):20- 30.

53. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. *Gerontologist.* 1969;9(3):179- 86.

54. Folstein MF, Folstein SE, McHugh PR. « Mini-mental state »: A practical method for grading the cognitive state of patients for the clinician. *J Psychiatr Res.* nov



1975;12(3):189- 98.

55. Yesavage JA, Brink TL, Rose TL et al. Development and validation of a geriatric depression screening scale: a preliminary report. *J Psychiatr Res.* 1983 1982;17(1):37- 49.
56. Mendoza TR, Wang XS, Cleeland CS et al. The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. *Cancer.* 1 mars 1999;85(5):1186- 96.
57. Oken MM, Creech RH, Tormey DC et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. *Am J Clin Oncol.* déc 1982;5(6):649- 55.
58. Mak PHK, Campbell RCH, Irwin MG et al. The ASA Physical Status Classification: inter-observer consistency. *American Society of Anesthesiologists. Anaesth Intensive Care.* oct 2002;30(5):633- 40.
59. Satariano WA, Ragland DR. The effect of comorbidity on 3-year survival of women with primary breast cancer. *Ann Intern Med.* 15 janv 1994;120(2):104- 10.
60. Huisman MG, Kok M, de Bock GH et al. Delivering tailored surgery to older cancer patients: Preoperative geriatric assessment domains and screening tools – A systematic review of systematic reviews. *Eur J Surg Oncol (EJSO).* janv 2017;43(1):1- 14.
61. Huisman MG, van Leeuwen BL, Ugolini G et al. « Timed Up & Go »: A Screening Tool for Predicting 30-Day Morbidity in Onco-Geriatric Surgical Patients? A Multicenter Cohort Study. Takabe K, éditeur. *PLoS ONE.* 24 janv 2014;9(1):e0086863.
62. Korc-Grodzicki B, Sun SW, Zhou Q et al. Geriatric Assessment as a Predictor of Delirium and Other Outcomes in Elderly Patients With Cancer. *Ann Surg.* juin 2015;261(6):1085- 90.
63. Brouquet A, Cudennec T, Benoist S et al. Impaired mobility, ASA status and administration of tramadol are risk factors for postoperative delirium in patients aged 75 years or more after major abdominal surgery. *Ann Surg.* avr 2010;251(4):759- 65.
64. Kim S, Han H-S, Jung H et al. Multidimensional frailty score for the prediction of

postoperative mortality risk. *JAMA Surg.* juill 2014;149(7):633- 40.

65. Repetto L. Greater risks of chemotherapy toxicity in elderly patients with cancer. *J Support Oncol.* déc 2003;1(4 Suppl 2):18- 24.

66. Kim J, Hurria A. Determining chemotherapy tolerance in older patients with cancer. *J Natl Compr Canc Netw.* 1 déc 2013;11(12):1494- 502.

67. Hurria A, Togawa K, Mohile SG et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. *J Clin Oncol.* 1 sept 2011;29(25):3457- 65.

68. Extermann M, Boler I, Reich RR et al. Predicting the risk of chemotherapy toxicity in older patients: The Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score: CRASH Score. *Cancer.* 1 juill 2012;118(13):3377- 86.

69. Balducci L, Extermann M. Management of cancer in the older person: a practical approach. *Oncologist.* 2000;5(3):224- 37.

70. Droz J-P, Aapro M, Balducci L et al. Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology. *Lancet Oncol.* août 2014;15(9):e404- 14.

71. Droz J-P, Albrand G, Gillessen S et al. Management of Prostate Cancer in Elderly Patients: Recommendations of a Task Force of the International Society of Geriatric Oncology. *Eur Urol.* oct 2017;72(4):521- 31.

72. Ferrat E, Audureau E, Paillaud E et al. Four Distinct Health Profiles in Older Patients With Cancer: Latent Class Analysis of the Prospective ELCAPA Cohort. *J Gerontol A Biol Sci Med Sci.* 1 déc 2016;71(12):1653- 60.

73. Ferrat E, Paillaud E, Caillet P et al. Performance of Four Frailty Classifications in Older Patients With Cancer: Prospective Elderly Cancer Patients Cohort Study. *J Clin Oncol.* mars 2017;35(7):766- 77.

74. Corre R, Greillier L, Le Caër H et al. Use of a Comprehensive Geriatric Assessment for the Management of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Phase III Randomized ESGIA-GFPC-GECP 08-02 Study. *J Clin Oncol*. 1 mai 2016;34(13):1476- 83.
75. Pallis AG, Ring A, Fortpied C et al. EORTC workshop on clinical trial methodology in older individuals with a diagnosis of solid tumors. *Ann Oncol*. 1 août 2011;22(8):1922- 6.
76. Hurria A, Gupta S, Zauderer M et al. Developing a cancer-specific geriatric assessment: a feasibility study. *Cancer*. 1 nov 2005;104(9):1998- 2005.
77. Paillaud E, Caillet P, Cudennec T et al. DIALOG task force for definition of a geriatric minimum data set for clinical oncology research. *Eur J Cancer*. 1 févr 2017;72:S114.